Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Over time, untreated high blood sugar can lead to serious and even life threatening complications. Type 2 diabetes also puts you at risk for certain health conditions that can reduce life ...

Johnson & Johnson (J&J) has shared positive results from a phase 3b study of Tremfya (guselkumab) in adults with psoriatic arthritis (PsA ... a significant reduction in the signs and symptoms of the ...

Initially disclosing a diagnosis of rheumatoid arthritis, he later revealed that he actually suffers from psoriatic arthritis - a chronic condition characterised by joint pain, swelling and ...

Adam also apologised to his followers for having not been "very vocal" about his experience with arthritis lately. He told them in the recent post on Instagram: "[I'm] just struggling and trying ...

Among a large cohort of young adults with psoriatic arthritis, 38.8% exhibited radiographic ... Please see the original reference for a full list of disclosures.

of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage measured by radiographic progression at 24 weeks, in adults living with active psoriatic ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its monoclonal antibody Tremfya (guselkumab) for active psoriatic arthritis (PsA).

For approximately 85% of patients diagnosed with psoriatic arthritis, the skin manifestations of psoriasis emerge first, with joint symptoms typically developing 7-10 years after initial skin ...